Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage‐colony‐stimulating factor in combination with standard induction chemotherapy: Effect of granulocyte macrophage‐colony‐stimulating factor on white blood cell counts Journal Article

  

Authors:	Valent, P.; Sillaber, C.; Geissler, K.; Andreeff, M.; Tafuri, A.; Vieder, L.; Schulz, G.; Lechner, K.; Bettelheim, P.
Article Title:	Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage‐colony‐stimulating factor in combination with standard induction chemotherapy: Effect of granulocyte macrophage‐colony‐stimulating factor on white blood cell counts
Abstract:	GM‐CSF is a major regulator of myelopoiesis. Recombinant human GM‐CSF (250 μg/m2 per day i.v.) was used prior to chemotherapy (“3 + 7” scheme) to recruit leukemia blasts in vivo (de novo AML patients, n = 20) into the chemotherapy sensitive phases of the cell cycle. The stimulatory effect of GM‐CSF on peripheral blood AML blasts was associated with a rapid redistribution of leukemia blood cells and with an increase in “S‐phase positive” cells. Standard induction chemotherapy (“3 + 7”) following GM‐CSF induced complete aplasia in 19/20 patients. In the same patients, rhGM‐CSF (given after chemotherapy) was found to shorten the time of complete aplasia compared to historical controls whereas post‐chemotherapy‐ and follow‐up data suggest no significant differences for CCR and survival. Together, our studies show that GM‐CSF can safely be administered to AML patients in combination with induction chemotherpay to recruit leukemia cells into the cell cycle. © 1992 Wiley‐Liss, Inc. Copyright © 1992 Wiley‐Liss, Inc., A Wiley Company
Keywords:	adult; aged; middle aged; survival rate; acute granulocytic leukemia; clinical trial; mortality; cytarabine; follow up; follow-up studies; antineoplastic agent; monitoring; phase 2 clinical trial; antineoplastic combined chemotherapy protocols; granulocyte macrophage colony stimulating factor; drug effect; blood; cytokines; recombinant proteins; recombinant protein; daunorubicin; remission; remission induction; leukocyte count; phase 1 clinical trial; aml; granulocyte-macrophage colony-stimulating factor; monitoring, physiologic; leukemia, myelocytic, acute; humans; human; male; female; article; recruitment of leukemia cells
Journal Title:	Medical and Pediatric Oncology
Volume:	20
Issue:	Suppl. 2
ISSN:	0098-1532
Publisher:	Wiley Liss
Date Published:	1992-01-01
Start Page:	18
End Page:	22
Language:	English
DOI:	10.1002/mpo.2950200705
PUBMED:	1306881
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-0027059340&doi=10.1002%2fmpo.2950200705&partnerID=40&md5=4d11b19ff3b2fc2ed8cb09d451fdffc0
Notes:	Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/149943